Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

 Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots:

  • Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors
  • The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis
  • NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and inflammatory disorders

Click here to read full press release/ article | Ref: Jecure Therapeutics | Image: Xconomy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post